Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia

Blood

Volumn 120, Issue 1, 2012, Pages 207-213

  Jácomo, Rafael H ^a,b   Santana Lemos, Barbara A ^a   Lima, Ana Silvia G ^a   Assis, Patricia A ^a   Lange, Ana Paula A ^a   Figueiredo Pontes, Lorena L ^a   Oliveira, Luciana O ^a   Bassi, Sarah C ^a   Benício, Mariana T L ^a   Baggio, Márcia S ^a   Garcia, Aglair B ^a   Falcão, Roberto P ^a   Rego, Eduardo Magalhães ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Unidade de Biologia Molecular Laboratório e Instituto Sabin   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; LCKLSL PEPTIDE; LIPOCORTIN 2; METHIONINE; PLASMINOGEN; PROTEIN P 36; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DISEASE MODEL; FIBRINOLYSIS; HYPERHOMOCYSTEINEMIA; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PICHIA; PICHIA METHANOLICA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN MOTIF; WILD TYPE;

EID: 84863582642     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-347187     Document Type: Article

References (31)

1. Tallman MS, Andersen JW, Schiffer CA, et al. Alltrans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021-1028. (Pubitemid 27430519)
2. Cordonnier C, Vernant JP, Brun B, et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer. 1985;55(1):18-25. (Pubitemid 15198193)
3. Jácomo RH, Melo RA, Souto FR, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007; 92(10):1431-1432. (Pubitemid 350144166)
4. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010; 115(25):5137-5146.
5. Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood. 1994; 84(9):3001-3009.
6. Zhu J, Guo WM, Yao YY, et al. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia. 1999;13(7):1062-1070. (Pubitemid 29360924)
7. Griffin JD, Rambaldi A, Vellenga E, Young DC, Ostapovicz D, Cannistra SA. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987;70(4):1218-1221. (Pubitemid 18022408)
8. Sterrenberg L, Haak HL, Brommer EJ, Nieuwenhuizen W. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis. 1985;15(2):126-133. (Pubitemid 15035500)
9. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood. 1991; 77(9):1949-1957.
10. Aoki N, Moroi M, Matsuda M, Tachiya K. The behavior of alpha2-plasmin inhibitor in fibrinolytic states. J Clin Invest. 1977;60(2):361-369. (Pubitemid 8154142)
11. Meijers JC, Oudijk EJ, Mosnier LO, et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol. 2000;108(3):518-523. (Pubitemid 30196247)
12. Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol. 1989;71(4):511-517. (Pubitemid 19121334)
13. Tapiovaara H, Alitalo R, Stephens R, Myöhänen H, Ruutu T, Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood. 1993; 82(3):914-919. (Pubitemid 23221675)
14. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340(13):994-1004. (Pubitemid 29157631)
15. Zhang X, Zhou H, Wang J, et al. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. Thromb Res. 2002;106(1):63-70. (Pubitemid 34879967)
16. Olwill SA, McGlynn H, Gilmore WS,Alexander HD. Annexin II cell surface and mRNAexpression in human acute myeloid leukaemia cell lines. Thromb Res. 2005;115(1-2):109-114. (Pubitemid 39572763)
17. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem. 1994;269(33):21198-21203.
18. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994;269(33):21191-21197.
19. He LZ, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A. 1997; 94(10):5302-5307. (Pubitemid 27214778)
20. Rego EM, Ruggero D, Tribioli C, et al. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene. 2006;25(13):1974-1979.
21. Santana BA, Pintão MC, Abreu e Lima RS, et al. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model. Braz J Med Biol Res. 2006;39(5): 615-620.
22. Sommeijer DW, van Oerle R, Reitsma PH, et al. Analysis of blood coagulation in mice: preanalytical conditions and evaluation of a homemade assay for thrombin-antithrombin complexes. Thromb J. 2005;3:12.
23. Ling Q, Jacovina AT, Deora A, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest. 2004;113(1):38-48. (Pubitemid 38541630)
24. Ishii H, Yoshida M, Hiraoka M, et al. Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res. 2001; 89(12):1240-1245. (Pubitemid 34627884)
25. Hajjar KA, Acharya SS. Annexin II and regulation of cell surface fibrinolysis. Ann N Y Acad Sci. 2000;902:265-271. (Pubitemid 30389131)
26. Kassam G, Choi KS, Ghuman J, et al. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem. 1998;273(8):4790-4799. (Pubitemid 28103230)
27. Avvisati G, ten Cate JW, Büller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989; 2(8655):122-124. (Pubitemid 19180573)
28. Keane TJ, GormanAM, O'Connell LG, Fennelly JJ. epsilon-Amino-caproic acid in the management of acute promyelocytic leukaemia. Acta Haematol. 1976;56(4):202-204.
29. Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med. 1986;105(6):873-877. (Pubitemid 17201762)
30. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMAgroup. Blood. 2004;103(4):1237-1243. (Pubitemid 38168633)
31. Hashimoto S, Koike T, Tatewaki W, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia. 1994;8(7):1113-1115. (Pubitemid 24224512)